Hepatocellular Carcinoma Clinical Trials in Seattle, Washington
8 recruitingSeattle, Washington
Showing 1–8 of 8 trials
Recruiting
Phase 2
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
Hepatocellular Carcinoma
Genentech, Inc.30 enrolled61 locationsNCT06096779
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb129 enrolled45 locationsNCT07291076
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1
Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Hepatocellular CarcinomaRhabdomyosarcomaWilms Tumor+7 more
Seattle Children's Hospital21 enrolled1 locationNCT07148050
Recruiting
Phase 3
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca1,220 enrolled204 locationsNCT06921785
Recruiting
Phase 1Phase 2
T-Cell Therapy (ECT204) in Adults With Advanced HCC
Hepatocellular CarcinomaMetastatic Liver CancerLiver Cancer, Adult+1 more
Eureka Therapeutics Inc.20 enrolled7 locationsNCT04864054
Recruiting
Phase 1Phase 2
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated178 enrolled21 locationsNCT05440708
Recruiting
Phase 1Phase 2
A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Advanced Hepatocellular Carcinoma
Iterion Therapeutics178 enrolled8 locationsNCT05797805